IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Caamtech Inc	Confirmation No.: 8925
Serial No.:	18/392,759	Group No.:
Filing or 371(c) Date:	December 21, 2023	Examiner:

Entitled: Tryptamine derivatives and their therapeutic uses

THIRD-PARTY PRE-ISSUANCE SUBMISSION

Examiner:

The following documents, which are also identified in the Form PTO/SB/429 filed herewith, are submitted for your consideration as being of potential relevance to the examination of the present application.

1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

Attached hereto is a claim chart providing a concise description of the relevance of each reference in the document list to the elements of the presently pending claims.

U.S.S.N. 18/392,759 Pending Claims	References
1. A tryptamine compound of formula (I):  wherein: R1 is a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl; R2 is —OR9; R3 is chosen from hydroxyl, —OR9, —OC(O)R8, or —OC(O)OR4, and —OSO2R4; R4 is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R8 is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R9 is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; and R5, R6 and R7 are each independently hydrogen or a straight chain or branched C1-C6 alkyl, or a pharmaceutically acceptable acid-addition salt thereof,	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen,** halogen, **C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl

with the proviso that when R2 is —OR9, R9 is a straight chain or branched C1-C6 alkyl.	
2. The tryptamine compound of claim 1, wherein R2 is —OR9 and R9 is methyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1**-C6 **alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl
3. The tryptamine compound of claim 1, wherein R2 is —OR9 and R9 is ethyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl;

	R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl
4. The tryptamine compound of claim 1, wherein R1 is selected from the group consisting of butyl, 2-butenyl, ethyl, isopropyl, propyl, allyl, vinyl, 1-methylethylidenyl, and 3-pentanyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl
5. The tryptamine compound of claim 1, wherein R3 is hydrogen and R2 is methoxyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**

	 (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl
6. A tryptamine compound selected from the group consisting of a compound of formula (II):  wherein: R1 is a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl; R2 and R3 are both hydrogen; R4 is —OR5; R6 is chosen from hydrogen, hydroxyl, —OR5, —OC(O)R11, —	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula Ila**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-;

OC(O)OR12, and —OSO2R12; R5 is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R11 is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R12 is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R7, R8 and R9 are each independently hydrogen or a straight chain or branched C1-C6 alkyl; and X− is a pharmaceutically acceptable anion, with the proviso that when R4 is —OR5, R5 is a straight chain or branched C1-C6 alkyl; and a compound of formula (IIa):  wherein: R1a is a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl; R2a and R3a are both hydrogen; R4a is —OR5a; R6a is chosen from hydrogen, hydroxyl, —OR5a, —OC(O)R11a,	**R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.**

—OC(O)OR12a, and —OSO2R12a; R5a is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R11a is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R12a is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R7a, R8a and R9a are each independently hydrogen or a straight chain or branched C1-C6 alkyl; and X2− is a pharmaceutically acceptable dianion, with the proviso that when R4a is —OR5a, R5a is a straight chain or branched C1-C6 alkyl.	
7. The tryptamine compound of claim 6, wherein the tryptamine compound is a compound of formula (II) and wherein R4 is —OR5 and R5 is methyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is** hydrogen, halogen**, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**;

	subscript q is an integer from 0 to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.**
8. The tryptamine compound of claim 6, wherein the tryptamine compound is a compound of formula (IIa) and wherein R4a is —OR5a and R5a is methyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable**

	salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.
9. The tryptamine compound of claim 6, wherein the tryptamine compound is a compound of formula (II) and wherein R4 is —OR5 and R5 is ethyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is** hydrogen, halogen**, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.**
10. The tryptamine compound of claim 6, wherein the tryptamine compound is a	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

compound of formula (IIa) and wherein R4a is —OR5a and R5a is ethyl.	From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula Ila**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is** hydrogen, halogen, **C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.**
11. The tryptamine compound of claim 6, wherein the tryptamine compound is a compound of formula (II) and R1 is selected from the group consisting of methyl, butyl, 2-butenyl, ethyl, isopropyl, propyl, allyl, vinyl, 1-methylethylidenyl, and 3-pentanyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula Ila**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl;

	R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.**
12. The tryptamine compound of claim 6, wherein the tryptamine compound is a compound of formula (IIa) and R1a is selected from the group consisting of methyl, butyl, 2-butenyl, ethyl, isopropyl, propyl, allyl, vinyl, 1-methylethylidenyl, and 3-pentanyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula Ila**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-;

	R8 is hydrogen, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.**
13. The tryptamine compound of claim 6, wherein the tryptamine compound is a compound of formula (II) and R6 is hydrogen and R4 is methoxyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including**

	racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.
14. The tryptamine compound of claim 6, wherein the tryptamine compound is a compound of formula (IIa) and R6a is hydrogen and R4a is methoxyl.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.**
15. A composition comprising a therapeutically effective amount of a tryptamine compound of claim 1 and a	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**

pharmaceutically acceptable excipient.	 (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.** From **[0169]**: **In some embodiments, the present invention provides a pharmaceutical composition including a pharmaceutically acceptable excipient** and a non-hallucinogenic analog of a psychedelic compound of the present invention.
16. A composition comprising a therapeutically effective amount of a tryptamine compound of claim 6 and a pharmaceutically acceptable excipient.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula Ila**

	 (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0169]**: **In some embodiments, the present invention provides a pharmaceutical composition including a pharmaceutically acceptable excipient** and a non-hallucinogenic analog of a psychedelic compound of the present invention.
17. A composition comprising a first active component: a tryptamine compound of claim 1; and a second active component selected from the group consisting of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a monoamine oxidase inhibitor, (e) a purified terpene, (f) a purified erinacine, (g) a purified hericenone, and (h) a purified	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula Ila**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**;

monoamine oxidase inhibitor.	**subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0169]**: **In some embodiments, the present invention provides a pharmaceutical composition including a pharmaceutically acceptable excipient and a non-hallucinogenic analog of a psychedelic compound of the present invention.**
18. A composition comprising a first active component: a tryptamine compound of claim 6; and a second active component selected from the group consisting of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a monoamine oxidase inhibitor, (e) a purified terpene, (f) a purified erinacine, (g) a purified hericenone, and (h) a purified monoamine oxidase inhibitor.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids**

	such as glutamic acid. These salts may be prepared by methods known to those skilled in art. From **[0169]**: **In some embodiments, the present invention provides a pharmaceutical composition including a pharmaceutically acceptable excipient and a non-hallucinogenic analog of a psychedelic compound of the present invention.**
19. A method of preventing or treating a psychological disorder comprising: identifying a subject in need of treatment or prevention; and administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0016]**: **The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder. The brain disorder can be a substance use disorder. And the brain disorder can be a neurodegenerative disorder including Alzhemier's and/or Parkinson's diseases.** From **[0061]**: **"Composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.**

20. A method of preventing or treating a psychological disorder comprising: identifying a subject in need of treatment or prevention; and administering to a subject in need thereof a therapeutically effective amount of the compound of claim 6.	1. Int'l Pat. App. Pub. No. WO/2018/064,465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa**  (IIa) **wherein:** **R9 is hydrogen,** C1-C6 alkyl, or C2-C6 alkenyl; **R10 is hydrogen, halogen, C1-C6 alkyl**, C2-C6 alkenyl, or Ci-C6 haloalkyl; **R11 is C1-C6 alkylamino**, di-(C1-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; **R12 is hydrogen**, halogen, **-OH**, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or **C1-C6 alkoxy**; **subscript q is an integer from 0** to 3; **L3 is a bond**, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; **R8 is hydrogen**, halogen, C1-G5 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl From **[0155]: The compounds of the present invention can also be the salts and isomers thereof. In some embodiments, the compounds of the present invention include the salt forms thereof. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)- tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art.** From **[0016]**: **The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder. The brain disorder can be a substance use disorder. And the brain disorder can be a neurodegenerative disorder including Alzhemier's and/or Parkinson's diseases.**

	From **[0061]**: **"Composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.**

UNITED STATES PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/392,759	**09/26/2024 11:06:04 AM Z ET**	

Title of Invention

Application Information

APPLICATION TYPE		PATENT #	
CONFIRMATION #		FILED BY	Jeremy Rolquin
PATENT CENTER #	67330086	FILING DATE	12/21/2023
CUSTOMER #	–	FIRST NAMED INVENTOR	
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	-

Documents

TOTAL DOCUMENTS: 5

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
third-party-preissuance-submission.pdf		2	Third-Party Submission Under 37 CFR 1.290	42 KB
Concise-description-generated.pdf		1	Concise Description of Relevance	23 KB
Third-party-notification-request.pdf		1	Request for Notification of Non-compliant Third-Party Submission	13 KB
CaaMTech US20240158349 3PS Embedded.pdf		19	-	189 KB
CaaMTech US20240158349 3PS Embedded-3P.RELEVANCE.pdf	(1-19)	19	Concise Description of Relevance	187 KB
WO2018064465-PAMPH-20180405-6727.pdf		85	-	4171 KB

WO2018064465-PAMPH-20180405-6727-FOR.pdf	(1-85)	85	Foreign Reference	4171 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
third-party-preissuance-submission.pdf	847533749387ACD6E6BF839B21EAB2278D5408D120D99DE51FEFD206A31929C7FC62F88672D3D40D2C00042110CC3A1F5948897925264652BF8F342F9347C76C
Concise-description-generated.pdf	467D0AB63F595FE149613CC619A457C5F28C61FB434AA24CC5ED7E244936FBB837B309896C1D44D8AF1F4155C805D468C967552C5BAF7BEB6B59DE86090DA25E
Third-party-notification-request.pdf	D0309DE961817DFFD21777C4DC6DB92020CC9B67A1BA0587249B2A936899570EAE66BB096EB22C01D5DFBDBCD9C43E9AFDA5E3CCD2035F34C80153C695FE3C00
CaaMTech US20240158349 3PS Embedded.pdf	3EF6403FD4B522B900F6B0AF830BCECEAF8FFDD9C04634D2EF951FDDE438086FA36F7CDD595C7EAFE27F116967D4CBC1A60754784165CD0588161C978517AFDF
CaaMTech US20240158349 3PS Embedded-3P.RELEVANCE.pdf	0073497A170B5EA944376BBD6E7B555FC205AD679D6F61E6D1A5755A254A294DBF1E1EFA3D0AE9206851066CDC99E816DA127607EB79215150A1BB61CD4A66AF
WO2018064465-PAMPH-20180405-6727.pdf	342390F82792A45048AF8A60110135A160330AFD4B31535C0F565F52A3B696D11E8B2998C240799E20AC88B09CB0707E0B84037416FE6807279392B278D391ED
WO2018064465-PAMPH-20180405-6727-FOR.pdf	4BE7569EB6C803AA41C2F1466C05C752E223E8370E289FE07D2F0F1727A02F01CBA06E2E0245E86547CAFFCDCB37EB59DFD8B817D0F8C3895E56E2E5811F8FD9

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security,

and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.